Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients
Status:
Recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This double-blind, randomized, placebo-controlled, investigator-initiated, multi-centre trial
aims to establish metabolic improvements in AD and PD subjects by dietary supplementation
with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine.
Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation will
stimulate to enhance hepatic β-oxidation and this study's hypothesis is that this will result
in increased mitochondrial activity in human brain cell-types.
Phase:
Phase 2
Details
Lead Sponsor:
Istanbul Medipol University Hospital
Collaborators:
Alanya Alaaddin Keykubat University KTH Royal Institute of Technology Sahlgrenska University Hospital, Sweden ScandiBio Therapeutics AB